| UHC Medicaid Medical & Drug | Rebyota® (Fecal Microbiota, Live-Jslm) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Respiratory Interleukins (Cinqair®, Fasenra®, & Nucala®) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Review at Launch for New to Market Medications – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Ryplazim® (Plasminogen, Human-Tvmh) – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Self-Administered Medications – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Simponi Aria® (Golimumab) Injection for Intravenous Infusion – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Sodium Hyaluronate – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Somatostatin Analogs – Community Plan Medical Benefit Drug Policy | 2026-04-01 |
| UHC Medicaid Medical & Drug | Subcutaneous Implantable Naltrexone Pellets – Community Plan Medical Benefit Drug Policy | 2026-04-01 |